Close Menu

NEW YORK — ProterixBio said on Wednesday that it has licensed a SARS-CoV-2 serology test from Massachusetts General Hospital.

According to ProterixBio, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein. The test can be run using dried blood samples from finger pricks and includes a means of calibration so measurements can be tracked over time.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.